Assessing effects of treatment with lisdexamfetamine dimesylate for pediatric ADHD using a parental survey
Donna Antonucci1, Craig Kunins, Michael Manos
1Center for Attention, Mood, and Behavior, St. Petersburg, FL, USA. dlantonuccimd@pol.net
Introduction:
Lisdexamfetamine dimesylate (LDX) is a prodrug stimulant approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6-12 years of age. Parent surveys provide valuable information regarding the impact of ADHD treatments.
Methods:
Parents of children with ADHD beginning treatment with LDX voluntarily completed surveys through an automated telephone system or the Internet before and 6 weeks after LDX treatment initiation. Prescribing physicians received individual reports of the responses for each survey completed by their patients' parents. All patients whose parents completed both baseline and 6 week surveys were included in the analyses. Subgroup analyses were conducted for those previously treated with medications to treat ADHD, including mixed amphetamine salts-extended release.
Results:
LDX treatment was associated with a significant decrease in ADHD symptom interference with school activities, family interactions, homework, and social interactions (P<.01; N=11,576). Parents rated satisfaction with LDX as significantly higher than with their child's previous treatment (P<.01). On average, global improvement, tolerability, convenience, and satisfaction with LDX were all highly rated.
Conclusion:
Patients treated with LDX showed significant symptom improvement and parents reported significantly greater satisfaction than with prior treatment.
